Clinical trials: sponsored by Innovent Biologics (Suzhou) Co. Ltd.
IgA Nephropathy (IgAN)
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study
- Trial name
- NCT07886476
- Testing
- IBI3034, Telitacicept
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight, Healthy Participants
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults.
- Conditions
- Overweight, Healthy Participants, Obesity
- Trial name
- NCT07793019
- Testing
- Orforglipron, IBI3042
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Participants, Overweight or Obese Participants
Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants
Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.
- Trial name
- NCT07765160
- Testing
- SAD: subcutaneous injection in the abdomen, MAD: subcutaneous injection in the abdomen
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Person
Clinical Trials of IBI3035 in Healthy Subjects
This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single…
- Trial name
- NCT07591519
- Testing
- IBI3035, Insulin icodec Injection
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Asthma
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
This study is a randomized, double-blind, placebo-controlled multiple dose ascending study in healthy participants and patients with asthma. Healthy participants will be enrolled in Part A and patients with asthma in Part B: 1.
- Trial name
- NCT06947408
- Testing
- IBI3002
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Acute Gout Flare
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare…
- Trial name
- NCT07295496
- Testing
- IBI3011
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Participants
A Mutiple-dose Study of IBI3033 in Healthy Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants.
- Trial name
- NCT07456839
- Testing
- IBI3033
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Participants
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants.
- Trial name
- NCT07311226
- Testing
- IBI3033
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Volunteers
A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers
This study is a multicenter, randomized, double-masked, parallel-group, reference-drug-controlled clinical trial of IBI3027 in healthy male volunteers.
- Trial name
- NCT07502534
- Testing
- IBI3027, DUPIXENT® (dupilumab)
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy, Active Non-segmental Vitiligo
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and…
- Conditions
- Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
- Trial name
- NCT07554222
- Testing
- Baricitinib tablets, IBI3013
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypertension,Essential
Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects.
- Trial name
- NCT06501586
- Testing
- SGB-3908
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Healthy Participants, Asthma
A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics
This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants…
- Trial name
- NCT06213844
- Testing
- IBI3002
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Participants, Atopic Dermatitis Patients
A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
- Trial name
- NCT06193434
- Testing
- IBI356 for MAD, Dupilumab for MAD, IBI356 for SAD
- Where
- China
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy
Safety and Tolerability of IBI355 in Healthy Volunteers
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of IBI355 in Healthy volunteers.
- Trial name
- NCT06416787
- Testing
- IBI355
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers
This trail will investigate the pharmacokinetics and safety of IBI310 and establish pharmacokinetics biosimilarity of IBI310 to ipilimumab （YERVOY）
- Trial name
- NCT04868760
- Testing
- Ipilimumab, IBI310
- Where
- China
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
Safety and Tolerance Study of IBI355 in Health Volunteers
This study is being done to find out if IBI355 is safe and tolerance in health volunteers. The study will test increasing single doses of IBI355 given to adult health volunteers.
- Trial name
- NCT06110338
- Testing
- IBI355
- Where
- China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Gout Arthritis
A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)
A Phase I study to evaluate the pharmacokinetic/pharmacodynamic characteristics,safety and tolerability of IBI128 after multidosing in Chinese health subjects.
- Trial name
- NCT06277752
- Testing
- dose-5 group, dose-1 group, dose-2 group
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Renal Impairment
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT05793450
- Testing
- IBI362
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
A Study of [14C]IBI351 in Healthy Subjects
This study is to evaluate the mass balance of single oral dose of [14C] IBI351 in healthy subjects. Six to eight healthy male subjects were planned to be enrolled.
- Trial name
- NCT05626179
- Testing
- [14C] IBI351
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight Subjects, Obese Subjects
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Trial name
- NCT05815680
- Testing
- metformin, digoxin, IBI362
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.